Brain
Cerebral infarction (ischaemic stroke)
Death of brain tissue in the territory of a blocked artery. The brain dies by liquefactive necrosis: macrophages clear it away, leaving a cyst walled by gliosis.
Causes and risk factors
- Embolic occlusion of a cerebral artery branch, the commonest cause
- Thrombosis, usually on marked cerebral atherosclerosis
- Global hypoperfusion (for example from low cardiac output): watershed infarcts between arterial territories
Gross pathology
- Acute: swollen brain in the territory of the artery, often the middle cerebral artery; embolic infarcts may be haemorrhagic from reperfusion.
- Subacute: soft, liquefying tissue beginning to form cystic spaces.
- Remote: a cystic defect surrounded by gliotic brain.
Under the microscope
- Macrophages filled with lipid debris from the liquefying brain.
- Vascular proliferation and reactive gliosis around the lesion.
How it develops
- Hours: Ischaemic neurons die; the infarct swells and may shift the midline.
- From 24 hours: Macrophages enter to remove the necrotic tissue.
- 10 days to 2 weeks: Liquefactive necrosis with cystic spaces; vessels proliferate and gliosis begins.
- From 2 weeks, for months: A cyst forms, walled by gliotic brain.
Complications
- Motor, sensory or visual deficits that depend on the territory (for example, visual field defects after a posterior cerebral infarct)
- Brain swelling with midline shift
- Recovery is partial and unpredictable, and less with age
Investigations
- CT of the head
- Excludes haemorrhage; an early infarct may not show, later appears as a dark (low-density) area.
- MRI with diffusion-weighted imaging
- Shows the infarct within minutes of onset.
- CT angiography
- The occluded artery.
- Carotid Doppler, ECG and echocardiography
- The source: carotid stenosis, atrial fibrillation or a thrombus in the heart.
Drug treatment
- Aspirin (COX-1 inhibitor): The antiplatelet drug of choice for preventing arterial thrombosis: one dose disables a platelet for the rest of its life.
- P2Y12 receptor antagonists: Antiplatelet drugs that block the ADP receptor on platelets; given with aspirin in acute coronary syndromes and after coronary stenting.
- Statins (HMG-CoA reductase inhibitors): The main drugs for lowering LDL cholesterol; they substantially reduce coronary events and deaths from coronary heart disease.
- Oral anticoagulants (warfarin and the direct oral anticoagulants): Tablets that prevent clots: warfarin blocks the vitamin K cycle; the direct oral anticoagulants (DOACs) inhibit thrombin or factor Xa. Used for venous thromboembolism and to prevent stroke in atrial fibrillation.
- Fibrinolytics (thrombolytics): Drugs that dissolve an existing clot by converting plasminogen to plasmin; given within hours for ST-elevation myocardial infarction, ischaemic stroke and massive pulmonary embolism.
Anatomy involved
Connected topics
Written from
- Robbins and Cotran Atlas of Pathology, 3rd ed., Ch. 19, The Central Nervous System, pp. 516–517, figs 19-65 to 19-70
Educational reference. Not medical advice, diagnosis or treatment.